KRAS and cancer: Cleaved PARP immunoblot assay revealed that treatment with AZ628 or BP-1-102 single selectively increased cleaved PARP protein levels in KRAS mutant cancer cells, while these inhibitors combination significantly induced cleaved PARP expression in these cells.